Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
John Mauldin Insider Profile
4 Followers
John Mauldin, Director at Galectin Therapeutics, holds 47.62K shares in Galectin Therapeutics (Ticker: GALT), holds ― shares in Serina Therapeutics (Ticker: SER).
John Mauldin has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that John Mauldin holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 26, 2012 - Apr 26, 2013
Return:+26.10%
The most profitable trade made by John Mauldin
John Mauldin's Trading History
Galectin Therapeutics
Jul 08, 2015
Director
Uninformative Buy
―
$154.28K
Serina Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see John Mauldin's performance on stock
You May Also Like
John Mauldin insider profile FAQ
What is the percentage of profitable transactions made by John Mauldin?
The percentage of profitable transactions made by John Mauldin is ―.
What is the average return per transaction made by John Mauldin?
The average return per transaction made by John Mauldin is ―.
What stocks does John Mauldin hold?
John Mauldin holds: GALT, SER stocks.
What was John Mauldin’s latest transaction?
John Mauldin latest transaction was an Uninformative Buy of ―.
What was John Mauldin's most profitable transaction?
John Mauldin’s most profitable transaction was an Informative Buy of GALT stock on April 26, 2012. The return on the trade was 26.10%.
What is John Mauldin's role in Galectin Therapeutics?
John Mauldin's role in Galectin Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.